FDC Quarterly Results for Trading Insights
Latest Quarter Net Profit
₹103 Cr
QMar 2026
In Mar 2026, FDC (FDC) reported revenue ₹635 Cr and net profit ₹103 Cr — revenue +25.0% YoY. Also explore FDC share price charts to track price trends across different timeframes.
FDC Quarterly Results — Revenue, Profit & EPS Highlights
FDC latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit FDC stock price BSE.
- Revenue of ₹635 Cr in Mar 2026 (+28.5% vs Sept 2025, +25.0% vs Mar 2025)
- Net Profit of ₹103 Cr in Mar 2026 (+267.9% vs Sept 2025, +164.1% vs Mar 2025)
- EBITDA of ₹156 Cr in Mar 2026 (+188.9% vs Sept 2025)
- Operating Margin of 18.0% in Mar 2026 (+11.0pp vs Sept 2025)
- Earnings Per Share of ₹6.35 in Mar 2026 (+262.9% vs Sept 2025)
FDC Quarterly Results — Revenue, EBITDA, Net Profit & EPS
FDC quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 635 | 494 | 508 | 684 | 486 | 28.5% | 25.0% |
| Net Profit (₹ Cr) | 103 | 28 | 39 | 121 | 28 | - | - |
| EBITDA (₹ Cr) | 156 | 54 | 70 | 176 | 52 | - | - |
| EPS (₹) | 6.35 | 1.75 | 2.38 | 7.45 | 1.74 | - | - |
| Operating Margin (%) | 18.0% | 7.0% | 11.0% | 22.0% | 7.0% | - | - |
FDC Share Price Trend — 1-Year Movement Across Quarterly Results
FDC 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Browse FDC balance sheet details for revenue, profit, balance sheet and cash flow data.
Revenue Trend (₹ Cr)
Jun 2025
684
Mar 2025
508
Sept 2025
494
Mar 2026
635
Net Profit Trend (₹ Cr)
Jun 2025
121
Mar 2025
39
Sept 2025
28
Mar 2026
103
Operating Margin Trend (%)
Jun 2025
22.0%
Mar 2025
11.0%
Sept 2025
7.0%
Mar 2026
18.0%
FDC vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
FDC latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹469,405.89 Cr | 1941.1 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 171.8 |
|
Divis Laboratories
Mar 2026 |
₹194,269.91 Cr | 7248.5 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 256.0 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹191,454.40 Cr | 4961.5 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 431.1 |
|
Zydus Life Science
Mar 2026 |
₹115,616.29 Cr | 1108.7 | 7,569 | 1,341 | +23.1% | +18.8% | 17.7% | 87.6 |
|
Cipla
Mar 2026 |
₹114,318.19 Cr | 1410.6 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 205.3 |
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores
All amounts in ₹ Crores